Skedgel Chris, Cubi-Molla Patricia, Mott David, Gameiro Sofia, Boivin Jacky, Al-Janabi Hareth, Brazier John, Markert Marie, Andersson Fredrik L, Jofre-Bonet Mireia
Office of Health Economics, Goldings House, 2nd Floor, Hay's Galleria, 2 Hay's Lane, London, SE1 2HB, UK.
School of Psychology, University of Cardiff, Cardiff, UK.
Pharmacoecon Open. 2023 May;7(3):337-344. doi: 10.1007/s41669-023-00402-5. Epub 2023 Mar 15.
An increasing number of prospective parents are experiencing infertility along with associated negative impacts on mental health and life satisfaction that can extend across a network of individuals and family members. Assistive reproductive technologies (ART) can help prospective parents achieve their parenthood goals but, like any health technology, they must demonstrate acceptable 'value for money' to qualify for public funding. We argue that current approaches to understanding the value of ART, including quality-adjusted life-year (QALY) gains based on changes in health-related quality of life (HRQOL) and, more often, cost per live birth, are too narrow to capture the full impact of unmet parenthood goals and ART. We see a fundamental disconnect between measures of HRQOL and broader measures of wellbeing associated with met and unmet parenthood goals. We also suggest that simple concepts such as 'patient' and 'carer' are of limited applicability in the context of ART, where 'spillovers' extend across a wide network of individuals, and the person receiving treatment is often not the infertile individual. Consideration of individual and societal wellbeing beyond HRQOL is necessary to understand the full range of negative impacts associated with unmet parenthood goals and the corresponding positive impacts of successful ART. We suggest moving towards a wellbeing perspective on value to achieve a fuller understanding of value and promote cross-sector allocative efficiency.
越来越多的准父母正面临不孕问题,以及由此对心理健康和生活满意度产生的负面影响,这些影响会波及个人和家庭成员网络。辅助生殖技术(ART)可以帮助准父母实现为人父母的目标,但与任何医疗技术一样,它们必须证明具有可接受的“性价比”才能获得公共资金。我们认为,目前理解ART价值的方法,包括基于健康相关生活质量(HRQOL)变化的质量调整生命年(QALY)增益,以及更常见的每例活产成本,过于狭隘,无法全面反映未实现的为人父母目标和ART的全部影响。我们看到HRQOL指标与与已实现和未实现的为人父母目标相关的更广泛的幸福感指标之间存在根本脱节。我们还认为,诸如“患者”和“护理者”等简单概念在ART背景下的适用性有限,因为“溢出效应”会波及广泛的个人网络,而且接受治疗的人往往不是不孕个体。有必要考虑HRQOL之外的个人和社会幸福感,以全面理解与未实现的为人父母目标相关的负面影响以及ART成功带来的相应积极影响。我们建议从幸福感角度看待价值,以更全面地理解价值并提高跨部门配置效率。